The Atypical Dopamine Transporter Inhibitor CE-158 Enhances Dopamine Neurotransmission in the Prefrontal Cortex of Male Rats: A Behavioral, Electrophysiological, and Microdialysis Study.
ADHD
chronic treatment
cognitive enhancer
dopamine transporter
prefrontal cortex
Journal
The international journal of neuropsychopharmacology
ISSN: 1469-5111
Titre abrégé: Int J Neuropsychopharmacol
Pays: England
ID NLM: 9815893
Informations de publication
Date de publication:
24 Nov 2023
24 Nov 2023
Historique:
received:
24
06
2023
accepted:
17
09
2023
medline:
27
11
2023
pubmed:
19
9
2023
entrez:
19
9
2023
Statut:
ppublish
Résumé
Dopamine plays a key role in several physiological functions such as motor control, learning and memory, and motivation and reward. The atypical dopamine transporter inhibitor S,S stereoisomer of 5-(((S)-((S)-(3-bromophenyl)(phenyl)methyl)sulfinyl)methyl)thiazole (CE-158) has been recently reported to promote behavioral flexibility and restore learning and memory in aged rats. Adult male rats were i.p. administered for 1 or 10 days with CE-158 at the dose of 1 or 10 mg/kg and tested for extracellular dopamine in the medial prefrontal cortex by means of intracerebral microdialysis and single unit cell recording in the same brain area. Moreover, the effects of acute and chronic CE-158 on exploratory behavior, locomotor activity, prepulse inhibition, working memory, and behavioral flexibility were also investigated. CE-158 dose-dependently potentiated dopamine neurotransmission in the medial prefrontal cortex as assessed by intracerebral microdialysis. Moreover, repeated exposure to CE-158 at 1 mg/kg was sufficient to increase the number of active pyramidal neurons and their firing frequency in the same brain area. In addition, CE-158 at the dose of 10 mg/kg stimulates exploratory behavior to the same extent after acute or chronic treatment. Noteworthy, the chronic treatment at both doses did not induce any behavioral alterations suggestive of abuse potential (e.g., motor behavioral sensitization) or pro-psychotic-like effects such as disruption of sensorimotor gating or impairments in working memory and behavioral flexibility as measured by prepulse inhibition and Y maze. Altogether, these findings confirm CE-158 as a promising pro-cognitive agent and contribute to assessing its preclinical safety profile in a chronic administration regimen for further translational testing.
Sections du résumé
BACKGROUND
BACKGROUND
Dopamine plays a key role in several physiological functions such as motor control, learning and memory, and motivation and reward. The atypical dopamine transporter inhibitor S,S stereoisomer of 5-(((S)-((S)-(3-bromophenyl)(phenyl)methyl)sulfinyl)methyl)thiazole (CE-158) has been recently reported to promote behavioral flexibility and restore learning and memory in aged rats.
METHODS
METHODS
Adult male rats were i.p. administered for 1 or 10 days with CE-158 at the dose of 1 or 10 mg/kg and tested for extracellular dopamine in the medial prefrontal cortex by means of intracerebral microdialysis and single unit cell recording in the same brain area. Moreover, the effects of acute and chronic CE-158 on exploratory behavior, locomotor activity, prepulse inhibition, working memory, and behavioral flexibility were also investigated.
RESULTS
RESULTS
CE-158 dose-dependently potentiated dopamine neurotransmission in the medial prefrontal cortex as assessed by intracerebral microdialysis. Moreover, repeated exposure to CE-158 at 1 mg/kg was sufficient to increase the number of active pyramidal neurons and their firing frequency in the same brain area. In addition, CE-158 at the dose of 10 mg/kg stimulates exploratory behavior to the same extent after acute or chronic treatment. Noteworthy, the chronic treatment at both doses did not induce any behavioral alterations suggestive of abuse potential (e.g., motor behavioral sensitization) or pro-psychotic-like effects such as disruption of sensorimotor gating or impairments in working memory and behavioral flexibility as measured by prepulse inhibition and Y maze.
CONCLUSIONS
CONCLUSIONS
Altogether, these findings confirm CE-158 as a promising pro-cognitive agent and contribute to assessing its preclinical safety profile in a chronic administration regimen for further translational testing.
Identifiants
pubmed: 37725477
pii: 7277241
doi: 10.1093/ijnp/pyad056
pmc: PMC10674083
doi:
Substances chimiques
Dopamine
VTD58H1Z2X
Dopamine Plasma Membrane Transport Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
784-795Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of CINP.
Références
Stress. 2018 Sep;21(5):443-452
pubmed: 29451062
BMC Biol. 2005 Feb 14;3:4
pubmed: 15710042
J Neurosci. 2022 Nov 9;42(45):8468-8476
pubmed: 36351822
J Neurosci. 2018 Feb 21;38(8):1959-1972
pubmed: 29348190
Cogn Process. 2018 Feb;19(1):107-115
pubmed: 28948389
Psychol Rep. 2005 Oct;97(2):631-8
pubmed: 16342593
Neuron. 2002 Mar 28;34(1):13-25
pubmed: 11931738
Pharmacol Rev. 2015 Oct;67(4):1005-24
pubmed: 26408528
Cell. 2016 Jan 14;164(1-2):208-218
pubmed: 26771492
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jan 10;88:222-234
pubmed: 30056065
Horm Behav. 2016 Jul;83:23-38
pubmed: 27189764
Biomolecules. 2020 May 18;10(5):
pubmed: 32443397
Brain Neurosci Adv. 2019 Feb 15;3:2398212818816018
pubmed: 32166175
Synapse. 1999 Dec 15;34(4):245-55
pubmed: 10529719
Mol Cell Neurosci. 2004 Apr;25(4):650-63
pubmed: 15080894
Annu Rev Neurosci. 2009;32:267-87
pubmed: 19555290
Brain Res. 2010 Mar 31;1322:92-101
pubmed: 20114036
Neurosci Biobehav Rev. 2002 Jan;26(1):91-104
pubmed: 11835987
Trends Cogn Sci. 2019 Mar;23(3):213-234
pubmed: 30711326
Biol Psychiatry. 2006 Nov 15;60(10):1111-20
pubmed: 16806100
Psychopharmacology (Berl). 2020 Nov;237(11):3459-3470
pubmed: 32770257
Pharmacol Rev. 2013 Dec 16;66(1):193-221
pubmed: 24344115
Nat Rev Neurosci. 2017 Nov 16;18(12):741-752
pubmed: 29142296
Biol Psychiatry. 2017 Jan 1;81(1):52-66
pubmed: 27452791
J Neurosci. 1998 Oct 1;18(19):8003-15
pubmed: 9742167
Front Behav Neurosci. 2017 Nov 27;11:222
pubmed: 29230168
Nat Rev Neurosci. 2002 Aug;3(8):617-28
pubmed: 12154363
Int Rev Neurobiol. 2018;141:131-172
pubmed: 30314595
Front Psychiatry. 2021 Dec 23;12:694863
pubmed: 35002789
Neuropsychopharmacology. 2017 Sep;42(10):2011-2020
pubmed: 28051103
Front Behav Neurosci. 2017 Jun 07;11:108
pubmed: 28638325
Biomolecules. 2022 Jun 24;12(7):
pubmed: 35883437
Front Behav Neurosci. 2016 Oct 18;10:202
pubmed: 27803654
Addict Behav. 2009 Apr;34(4):380-5
pubmed: 19097704
Nature. 2013 Jun 20;498(7454):363-6
pubmed: 23708967
Front Cell Neurosci. 2017 Jun 02;11:158
pubmed: 28626390
Neuropsychopharmacology. 2009 Apr;34(5):1089-90
pubmed: 19194378
Neuropsychopharmacology. 2002 Nov;27(5):699-711
pubmed: 12431845
Behav Brain Res. 2018 May 2;343:83-94
pubmed: 29410048
Front Pharmacol. 2019 Jun 28;10:682
pubmed: 31316379
Methods Mol Biol. 2019;1916:105-111
pubmed: 30535688
Psychopharmacology (Berl). 2001 Jul;156(2-3):117-54
pubmed: 11549216
Biol Psychiatry. 2015 Jun 1;77(11):940-50
pubmed: 25499957
Front Biosci. 2001 Sep 01;6:D1069-72
pubmed: 11532605
Biomolecules. 2023 Mar 03;13(3):
pubmed: 36979402
Mol Psychiatry. 2021 Dec;26(12):7076-7090
pubmed: 34244620
Eur J Pharmacol. 1992 Nov 3;222(1):7-12
pubmed: 1361442
Pharmacol Rev. 2011 Mar;63(1):182-217
pubmed: 21303898
Curr Neuropharmacol. 2016;14(1):87-100
pubmed: 26391743
Front Mol Neurosci. 2022 Jul 22;15:971349
pubmed: 35935333
Eur Neuropsychopharmacol. 2015 Nov;25(11):1865-81
pubmed: 26381811
PLoS One. 2011;6(10):e25790
pubmed: 22043293
Behav Neurosci. 2021 Feb;135(1):32-38
pubmed: 33734732
Transl Psychiatry. 2021 Dec 3;11(1):612
pubmed: 34857741
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 8;105:110128
pubmed: 33031862
Eur Neuropsychopharmacol. 2011 Feb;21(2):192-204
pubmed: 21146374
Can J Psychiatry. 1999 Oct;44(8):811-3
pubmed: 10566114
J Med Chem. 2020 Jan 9;63(1):391-417
pubmed: 31841637
J Psychopharmacol. 2014 Mar;28(3):254-69
pubmed: 24327450
Trends Neurosci. 1990 Mar;13(3):99-104
pubmed: 1691879
Eur Neurol. 1990;30 Suppl 1:15-20
pubmed: 2178937
Mol Neurobiol. 2019 May;56(5):3563-3575
pubmed: 30151725
Biol Psychiatry. 2010 Feb 1;67(3):199-207
pubmed: 19833323
Neurosci Biobehav Rev. 2022 Jun;137:104674
pubmed: 35452744
Psychopharmacology (Berl). 2001 Jul;156(2-3):194-215
pubmed: 11549223
Biomedicines. 2022 Sep 20;10(10):
pubmed: 36289598
Pharmacol Biochem Behav. 1988 Jun;30(2):535-7
pubmed: 3174785
J Psychopharmacol. 2007 Nov;21(8):795-804
pubmed: 17984160
Behav Brain Res. 2007 Aug 22;182(1):103-8
pubmed: 17574689
J Neurosci. 2015 Jul 15;35(28):10172-87
pubmed: 26180194
Biomolecules. 2022 Mar 27;12(4):
pubmed: 35454095
Neurosci Biobehav Rev. 1998;23(2):189-96
pubmed: 9884112
Neuropsychopharmacology. 2002 Aug;27(2):163-70
pubmed: 12093590
Trends Neurosci. 2021 Jul;44(7):550-563
pubmed: 33972100
Brain Res Bull. 2006 Feb 15;68(6):393-405
pubmed: 16459193
Cell Rep. 2019 Apr 2;27(1):99-114.e6
pubmed: 30943418
Cell Mol Neurobiol. 2019 Jan;39(1):31-59
pubmed: 30446950
Neuroscience. 2005;135(2):385-94
pubmed: 16125865
Arch Gen Psychiatry. 1990 Feb;47(2):181-8
pubmed: 2405807
Addict Behav. 2018 May;80:154-160
pubmed: 29407687
Neuroscience. 2017 Mar 14;345:203-217
pubmed: 27282085
Annu Rev Pharmacol Toxicol. 2003;43:261-84
pubmed: 12359863
J Neurosci. 2002 May 1;22(9):3312-20
pubmed: 11978805
Brain Res Brain Res Rev. 2003 Mar;41(2-3):203-28
pubmed: 12663081
Neurosci Biobehav Rev. 2022 Apr;135:104569
pubmed: 35131398
Brain Sci. 2022 Jun 24;12(7):
pubmed: 35884633
Pharmacol Res. 2010 Sep;62(3):187-206
pubmed: 20416377
Front Behav Neurosci. 2020 Apr 20;14:58
pubmed: 32372926
Psychopharmacology (Berl). 2016 Jan;233(2):225-33
pubmed: 26449721
Pharmacol Res. 2016 Jul;109:108-18
pubmed: 26826399
Eur J Neurosci. 2017 Jan;45(1):167-174
pubmed: 27545285
Behav Brain Res. 2015 Mar 15;281:177-86
pubmed: 25497705
Psychopharmacology (Berl). 2013 Oct;229(3):415-34
pubmed: 23934211
Neuroscience. 2006 Sep 1;141(3):1113-21
pubmed: 16750891
Schizophr Res. 2012 Apr;136(1-3):88-95
pubmed: 22104138
CNS Spectr. 2009 Sep;14(9):503-13
pubmed: 19890232
Prog Brain Res. 2000;126:433-53
pubmed: 11105661